Nakamoto Yuji, Baba Shingo, Kaida Hayato, Manabe Osamu, Uehara Tomoya
Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.
Ann Nucl Med. 2024 Jan;38(1):10-19. doi: 10.1007/s12149-023-01873-6. Epub 2023 Oct 20.
Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using F-fluorodeoxyglucose (FDG). Moreover, FAPI PET can identify malignant lesions that may be inconclusive on FDG PET. Beyond its application in neoplastic disorders, there have been encouraging reports suggesting the utility of FAPI PET in non-neoplastic conditions such as respiratory or cardiac diseases. This article aimed to provide a comprehensive overview of the recently published articles investigating FAPI and discuss its clinical utility with an emphasis on its application in tumor diagnostics. Numerous radiopharmaceutical FAPIs, including F- and Ga-labeled compounds, have been developed, and they offer various advantages and applications. With the progress in the FAPI PET synthesis to enhance accumulation and retention in pathological lesions, future studies are expected to provide valuable data on its therapeutic efficacy.
最近，使用成纤维细胞活化蛋白抑制剂（FAPI）的正电子发射断层扫描（PET）作为一种先进的肿瘤诊断成像工具受到了广泛关注。FAPI PET具有准确描绘大多数恶性肿瘤的能力，因此具有广阔的应用前景。它的准确性与使用F-氟脱氧葡萄糖（FDG）的PET诊断准确性相当甚至更高。此外，FAPI PET能够识别出在FDG PET上可能不明确的恶性病变。除了在肿瘤疾病中的应用，还有一些令人鼓舞的报告表明FAPI PET在非肿瘤性疾病如呼吸系统或心脏疾病中也具有实用价值。本文旨在全面概述最近发表的关于FAPI的研究文章，并讨论其临床应用，重点是其在肿瘤诊断中的应用。已经开发了许多放射性药物FAPI，包括F和Ga标记的化合物，它们具有各种优点和应用。随着FAPI PET合成技术的进步以增强在病理病变中的积聚和滞留，未来的研究有望提供有关其治疗效果的有价值数据。
